Alpharma Plans NDA Filing For Abuse-Deterrent Opioid In 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trial revealed that the extended-release opioid, ALO-01, demonstrated significant pain relief.
You may also be interested in...
Pain Therapeutics Ends Year Flush, “Slightly Ahead” Of Alpharma
Abuse-deterrent pain drug market big enough for all, analyst tells “The Pink Sheet” DAILY.
Pain Therapeutics Ends Year Flush, “Slightly Ahead” Of Alpharma
Abuse-deterrent pain drug market big enough for all, analyst tells “The Pink Sheet” DAILY.
Alpharma To Launch First Topical NSAID Patch Flector In January
Ramp up to the launch includes a nearly three-fold increase in Alpharma’s sales capacity.